Published in Antiviral Res on January 01, 1997
Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology (1997) 4.96
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis (2001) 3.69
Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol (2000) 3.54
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis (1998) 3.47
Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. Virology (1998) 3.09
A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J Virol Methods (1992) 2.32
Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology (1999) 2.31
Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology (1993) 2.27
Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs. Virology (1998) 1.60
Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides. Glycoconj J (1993) 1.56
Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. Virology (1998) 1.42
H5N1 chicken influenza viruses display a high binding affinity for Neu5Acalpha2-3Galbeta1-4(6-HSO3)GlcNAc-containing receptors. Virology (2004) 1.34
Differences between influenza virus receptors on target cells of duck and chicken and receptor specificity of the 1997 H5N1 chicken and human influenza viruses from Hong Kong. Avian Dis (2003) 1.26
Differences between HA receptor-binding sites of avian influenza viruses isolated from Laridae and Anatidae. Avian Dis (2003) 1.26
Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. Virus Res (2000) 1.19
Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology (1999) 1.09
Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein. Glycoconj J (1997) 1.06
GlycoChip: multiarray for the study of carbohydrate-binding proteins. Lab Chip (2003) 1.04
Synthetic polymeric sialoside inhibitors of influenza virus receptor-binding activity. FEBS Lett (1990) 1.01
Design of carbohydrate multiarrays. Biochim Biophys Acta (2006) 0.99
Mammalian galectins: structure, carbohydrate specificity, and functions. Biochemistry (Mosc) (2008) 0.99
Influenza virus neuraminidase: structure and function. Acta Naturae (2009) 0.98
Receptor specificity of H5 influenza virus escape mutants. Virus Res (2004) 0.96
Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides. Biochemistry (Mosc) (2006) 0.94
Amino acid changes in the hemagglutinin and matrix proteins of influenza a (H2) viruses adapted to mice. Acta Virol (2000) 0.92
Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants. Arch Virol (2007) 0.92
[The effect of losing glycosylation sites near the receptor-binding region on the receptor phenotype of the human influenza virus H1N1]. Mol Biol (Mosk) (2003) 0.92
Polymer-bound 6' sialyl-N-acetyllactosamine protects mice infected by influenza virus. Antiviral Res (2005) 0.91
Design of the blood group AB glycotope. Glycoconj J (2005) 0.90
Endogenous lectins as targets for drug delivery. Adv Drug Deliv Rev (2000) 0.88
Structure, functions, and biosynthesis of glycoconjugates of Leishmania spp. cell surface. Biochemistry (Mosc) (2010) 0.87
Hydrogel glycan microarrays. Anal Biochem (2005) 0.87
[Differences in receptor specificity between the influenza A viruses isolated from the duck, chicken, and human]. Mol Biol (Mosk) (2002) 0.87
Human influenza virus recognition of sialyloligosaccharides. FEBS Lett (1995) 0.86
Purification and characterization of tRNA (adenine-1-)-methyltransferase from Thermus flavus strain 71. Eur J Biochem (1982) 0.86
Association of prognosis in surgically treated lung cancer patients with cytometric, histometric and ligand histochemical properties: with an emphasis on structural entropy. Anal Quant Cytol Histol (1998) 0.86
Reverse lectin histochemistry: design and application of glycoligands for detection of cell and tissue lectins. Histol Histopathol (1993) 0.85
On the mechanism of tRNA methylase-tRNA recognition. Nucleic Acids Res (1976) 0.85
Synthetic polymeric inhibitors of influenza virus receptor-binding activity suppress virus replication. Antiviral Res (1994) 0.85
Fucoidan inhibits leukocyte recruitment in a model peritoneal inflammation in rat and blocks interaction of P-selectin with its carbohydrate ligand. Biochem Mol Biol Int (1997) 0.84
Xenotransplantation: in vitro analysis of synthetic alpha-galactosyl inhibitors of human anti-Galalpha1-->3Gal IgM and IgG antibodies. Glycobiology (2000) 0.84
Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer (1994) 0.84
Influenza viruses differ in recognition of 4-O-acetyl substitution of sialic acid receptor determinant. Virology (1992) 0.83
Search for additional influenza virus to cell interactions. Glycoconj J (2006) 0.83
Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. J Surg Oncol (1996) 0.83
Scintillation proximity assay for E-, P-, and L-selectin utilizing polyacrylamide-based neoglycoconjugates as ligands. Anal Biochem (1998) 0.83
Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis (2001) 0.83
An E-selectin binding assay based on a polyacrylamide-type glycoconjugate. Anal Biochem (1996) 0.83
Sialoside-binding macrophage lectins in phagocytosis of apoptotic bodies. Biochemistry (Mosc) (2005) 0.82
Fluorescent assay for studying the substrate specificity of neuraminidase. Anal Biochem (2005) 0.82
Modified blood group A trisaccharide probes: synthesis and interaction with antibodies. Carbohydr Lett (2001) 0.81
Specificity of monoclonal antibodies against ABH and related structures tested by ELISA with synthetic glycoconjugates. Transfus Clin Biol (1997) 0.81
A new combined computational and NMR-spectroscopical strategy for the identification of additional conformational constraints of the bound ligand in an aprotic solvent. Chembiochem (2000) 0.81
Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection. Antiviral Res (2002) 0.81
New feature of angiotensin-converting enzyme: carbohydrate-recognizing domain. J Mol Recognit (2000) 0.81
High-resolution atomic force microscopy study of hexaglycylamide epitaxial structures on graphite. Langmuir (2011) 0.81
[Modification of the target cell surface with lipophilic glycoconjugates and interaction of the modified cells with natural killer cells]. Bioorg Khim (2004) 0.81
Monoclonal antibodies directed to the synthetic carbohydrate antigen Ley. Hybridoma (1994) 0.80
Breast cancer-associated antibody LU BCRU G7 recognises the terminal disaccharide Gal beta 1-3GlcNAc and can be used to isolate tumour cells from body fluids by an immunomagnetic bead procedure. Biochem Soc Trans (1995) 0.80
A novel pentaglycosylceramide in ostrich liver, IV4-beta-Gal-nLc4Cer, with terminal Gal(beta1-4)Gal, a xenoepitope recognized by human natural antibodies. Glycobiology (2000) 0.80
[Molecular forms of alpha-1-acid glycoprotein in human blood serum. Differences in levels of di-, tri-, and tetra-antennary N-linked carbohydrate chains]. Bioorg Khim (1991) 0.80
[The interaction of peripheral blood leukocytes with alpha1-acid glycoprotein, its carbohydrate chains and neoglycoconjugates]. Gematol Transfuziol (1996) 0.80
Preneoplasia-associated expression of calcyclin and of binding sites for synthetic blood group A/H trisaccharide--exposing neoglycoconjugates in human lung. Cancer Biochem Biophys (1997) 0.80
In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. J Cancer Res Clin Oncol (1999) 0.80
Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer. Breast Cancer Res Treat (2005) 0.80
Coexpression of binding sites for A(B) histo-blood group trisaccharides with galectin-3 and Lag antigen in human Langerhans cells. J Leukoc Biol (1999) 0.80
[Sulfated polysaccharides as inhibitors of receptor activity of P-selectin and P-selectin-dependent inflammation]. Vopr Med Khim (1998) 0.80
Specificity of human anti-carbohydrate IgG antibodies as probed with polyacrylamide-based glycoconjugates. Glycoconj J (2004) 0.80
[Inhibitory activity of monomeric and polymeric selectin ligands]. Vopr Med Khim (2000) 0.80
[Conjugates and carbohydrate chains of alpha 1-acid glycoprotein with polyacrylamide maintain the immunomodulating activity of native glycoprotein]. Bioorg Khim (1995) 0.80
[Immunomodulating effects of alpha1-acid glycoprotein (orosomucoid) in cultured human peripheral blood lymphocytes]. Biull Eksp Biol Med (1994) 0.80
An enzyme-linked lectin assay for alpha1,3-galactosyltransferase. Anal Biochem (2000) 0.80
Binding sites for carrier-immobilized carbohydrates in the kidney: implication for the pathogenesis of Henoch-Schönlein purpura and/or IgA nephropathy. Nephrol Dial Transplant (1999) 0.79
[A possible association of fatal pneumonia with mutations of pandemic influenza A/H1N1 sw1 virus in the receptor-binding site of the HA1 subunit]. Vopr Virusol (2010) 0.79
Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe(X), in a mouse mammary adenocarcinoma model. Eur J Cancer (2000) 0.79
Human tandem-repeat-type galectins bind bacterial non-βGal polysaccharides. Glycoconj J (2013) 0.79